Fiche centre
SUNY Upstate Medical University
Syracuse — United States
Essais liés17clinical trials
VilleSyracuselocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06870812
Essais cliniques associés
17| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| NRTX-1001 | Épilepsie | Phase 3 | NCT05135091 | Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy)) | RECRUITING |
| Nivolumab | Cancer | Phase 3 | NCT06561386 | RELATIVITY1093 — A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | RECRUITING |
| Surgical management | Accident vasculaire cérébral | Non applicable | NCT06870812 | REACH — Rapid Evacuation and Access of Cerebral Hemorrhage Trial | RECRUITING |
| Nicotine Transdermal Patch | Alzheimer | Phase 2 | NCT02720445 | Memory Improvement Through Nicotine Dosing (MIND) Study | COMPLETED |
| Low Dose Benfotiamine | Alzheimer | Phase 2 | NCT06223360 | A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) | ACTIVE_NOT_RECRUITING |
| MN-166 | Sclérose latérale amyotrophique | À vérifier | NCT06743776 | SEANOBI-ALS — Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS | NO_LONGER_AVAILABLE |
| ACP-204 | Alzheimer | Phase 2/3 | NCT06159673 | ACP-204 in Adults With Alzheimer's Disease Psychosis | RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| KarXT | Alzheimer | Phase 3 | NCT06585787 | A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | RECRUITING |
| XEN1101 | Épilepsie | Phase 3 | NCT05667142 | X-ACKT — A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | RECRUITING |
| XEN1101 | Épilepsie | Phase 3 | NCT05718817 | X-TOLE4 — An Open-label Study of XEN1101 in Epilepsy | ENROLLING_BY_INVITATION |
| extended release metformin | Alzheimer | Phase 2/3 | NCT04098666 | MAP — Metformin in Alzheimer's Dementia Prevention | ACTIVE_NOT_RECRUITING |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT04569084 | Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS | TERMINATED |
| Ocrelizumab Test Formulation | SEP | Phase 2 | NCT07074886 | PORTAMENTO — A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) | ACTIVE_NOT_RECRUITING |
| Sacituzumab govitecan-hziy | Cancer | Phase 3 | NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | ACTIVE_NOT_RECRUITING |
| Fenebrutinib | SEP | Phase 3 | NCT04544449 | FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| baclofen | Myopathies | Phase 1 | NCT00607542 | Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity | COMPLETED |